On December 14, Beijing Hotgen Biotech Co., Ltd. (abbreviated as Hotgen Biotech, stock code: 688068) announced that the company intends to acquire 38.0993% equity interest in Oriomics by way of equity transfer and subscription of additional registered capital at a price of CNY 153 million.

Circulating tumor cells (CTC), circulating tumor cell DNA (ctDNA) and exosomes are the most popular liquid biopsy "troika" in the field of early cancer screening today, each with its own characteristics and advantages. Hotgen Biotech has already laid out the serological protein marker and exosome tests for liver cancer, and this time it has joined hands with Oriomics, which specializes in ctDNA methylation testing, thus deepening its layout in the field of early screening and diagnosis of liver cancer, and "from point to point", forming a multi-omics and multi-technology platform for synergistic development, and continuously extending to other high-incidence single cancer species and pan-cancer species. Hotgen Biotech will continue to expand into the field of early screening for other high-incidence single cancers and pan-cancer types.

The cooperation between Hotgen Biotech and Oriomics will jointly improve the layout of its multi-omics technology platform for early screening of cancer, whether in the development of liver cancer early screening products or other single cancer and pan-cancer products, which is in line with Oriomics ' strategic direction to build a "health management system from hepatitis to liver cancer" and to "continue to focus on the innovation and industrialisation of products in the field of medical and public safety testing". It is also a positive response to the important national strategic plan for cancer prevention and treatment.

About Hotgen Biotech

Beijing Hotgen Biotech Co., Ltd. (abbreviated as Hotgen Biotech, stock code: 688068) was established in June 2005, which is a high-tech enterprise focusing on the research& development, manufacture and sales of medical and public safety inspection products of in vitro diagnostics (IVD) in the field of biomedicine, as well as landed on the China Sci-Tech innovation board (STAR Market) in September 2019.

After serval years of Research& development, Hotgen Biotech has developed an in vitro diagnostic reagent bioactive raw material development platform, a sugar chain abnormal protein detection (sugar capture) R&D technology platform, a Magnetic particles chemiluminescence R&D technology platform, a Up-converting Phosphor R&D technology platform, and a colloidal gold immune layer, The eight major technology platforms, such as the precipitation R&D platform, enzyme-linked immunoassay R&D technology platform, molecular diagnostics R&D platform, and instrument R&D technology platform, form a closed-loop system for in vitro diagnostic R&D and production. Hotgen Biotech has established a complete full level immunodiagnostic technology platform, from high-precision Up-converting Phosphor POCT (UPT series) to small, medium and large single- cartridge chemiluminescence platforms (MQ60 series), and then to large-scale full-automatic chemiluminescence Platform (C2000), which realizes the application of the immune diagnostic platform in the field of full diagnostic scenarios. Supporting products are widely used in the clinical and public safety fields. Specific users include hospitals at all levels, township health centers, third-party testing centers, and medical institutions, as well as medical and health institutions, as well as disease control centers, public security, fire protection, military, ports, food and medicine. Supervision, food and feed enterprises and other public safety fields.

About Oriomics

Oriomics is a Class A key high-tech enterprise introduced by the government of Hangzhou Economic and Technological Development Zone, focusing on non-invasive early screening of tumors and precision cancer diagnosis.

Oriomics accurately grasps the general trend of tumor precision treatment and full management, and through continuous technological innovation and optimization, expands the development, production, sales and testing services of the whole process of tumor diagnosis products. Relying on a strong biotechnology information analysis team, the company has established a perfect technical route for early screening and early diagnosis of tumours by adopting non-invasive liquid biopsy technology, using next-generation sequencing technology as a platform and combining it with its original two-layer machine analysis core algorithm based on big data artificial intelligence analysis to analyse and compare copy number variants and tumour methylation characteristics at the genome-wide level for early cancer patients. We have successfully developed a highly sensitive and specific liver cancer early screening product, LIVECARE, using this technology. In addition to early screening and diagnosis of liver cancer, this technology can be extended to other cancers such as lung, stomach, bowel, breast, ovarian and cervical cancers.